All News
#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Over 10 years in the GESPIC cohort, males with #axSpA had lower ASDAS/BASDAI and enthesitis but double the odds of significant spinal radiographic progression vs females (OR 2.08). Symptoms don’t always correlate to structural damage Abstr OP0101 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776
Jiha Lee JihaRheum ( View Tweet)
JAKi vs ABA in RA-ILD: emulated target trial (n=1,162), JAKi with worse composite respiratory outcomes (HR 1.57) and all-cause mortality (HR 1.59) vs ABA over 5 yrs. JAKi with ↑ pneumonia risk. In RA-ILD, ABA may be the preferred choice? @RheumNow #EULAR2026 POS0813 #EULARBEST
Jiha Lee JihaRheum ( View Tweet)
Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810
Jiha Lee JihaRheum ( View Tweet)
What defines MRI indicative of axSpA?
This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity.
Time for updated definitions?
AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3
sheila RHEUMarampa ( View Tweet)
ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure
MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score
Potential adjunct tx for NPSLE?
AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s
sheila RHEUMarampa ( View Tweet)
@RheumNow WIN Nutrition session #EULAR2026 (4)
🌾 Gluten does NOT influence biologic response in RD, BELIEVE cohort, 197 pts. No need to go gluten-free unless celiac disease
🌱 Plants for Joints trial: plant-based diet + exercise → sustained DAS28&WOMAC improvement @ 2Y, RA/OA
@RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
@RheumNow WIN Nutrition session at #EULAR2026 (3)
6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal
7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001).
@RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
WIN Nutrition session at #EULAR2026 (2)
🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals.
🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies.
@RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
WIN Nutrition session at #EULAR2026 (1)
🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onset
🥩 Highest quartile of red & processed meat intake → nearly DOUBLE the risk of RA onset (OR 1.92, CI 1.11–3.35)
@rheumnow https://t.co/RhO08FXtLI
Nelly ZIADE 🍀 Nellziade ( View Tweet)
COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA
6 pts median 6.5 b/tsDMARDs
Single CAR T infusion after lymphodepletion
Safety
-CRS only grade 1–2 (no severe events)
-No ICANS
-Transient neutropenia
-No unexpected toxicities
Efficacy
DAS28-CRP ↓ ~41% median
50% achieved https://t.co/cdEfGKcJUp
Aurelie Najm AurelieRheumo ( View Tweet)
D2T RA shows a linked brain–psychology–immune signature
Cohort D2T RA vs non-D2T RA vs HC
91% D2T RA
Higher catastrophizing
Higher pain sensitivity
More emotion-focused coping strategies
“Chronic pain-like” profile
Associated with higher CNS related gene expression NRG1 https://t.co/nkQco73vqI
Aurelie Najm AurelieRheumo ( View Tweet)
Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach),
Non peptide based (can be given anytime). Know about s/e and contraindications.
May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar.
#EULAR2026 @RheumNow https://t.co/KNudYN29PT
Links:
Bella Mehta bella_mehta ( View Tweet)
Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow.
Average age 28! 87%female, only 7 % with psychiatric referral!
Retrospective 15 pts. https://t.co/241SE6O395
Links:
Bella Mehta bella_mehta ( View Tweet)
#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh
Mrinalini Dey DrMiniDey ( View Tweet)
Impt pts to consider in D2T CLE by Prof Wittmann:
If tx is not working, ask yourself: is the dx correct? adherence?
Main message: treat early
When damage is present, tx doesn’t really provide considerable improvements
Future drxns? Endotype-directed tx
@Rheumnow #EULAR2026 https://t.co/hB48aD7jx5
Links:
sheila RHEUMarampa ( View Tweet)
#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0
Mrinalini Dey DrMiniDey ( View Tweet)
Weight management should be discussed!!
Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist.
Best evidence in OA and Gout.
#EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu
Bella Mehta bella_mehta ( View Tweet)
Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow
Inflammation triggered by metabolic abnormalities.
This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.
Bella Mehta bella_mehta ( View Tweet)
